Bayer today announced the recent appointments of Rebecca Jolley as senior vice president and commercial head, Oncology and Dr. Scott Z. Fields, senior vice president and pharmaceutical development head, Oncology. Both are members of the Oncology Leadership Team and report to Robert LaCaze, executive vice president and head of the Oncology Strategic Business Unit.
"It is important that we stay focused on the science coupled with speed and agility to help bring important new medications and indications to patients as quickly and prudently as possible" said LaCaze. "Scott's global product development expertise combined with Rebecca's experience in successfully bringing products to market strengthens our ability to get medicines to patients."
Previously, Jolley served as senior vice president, Americas Commercial, Oncology Business Group at Eisai, where she was responsible for leading the Oncology commercial strategy and implementation across all approved products and pipeline assets. Prior to joining Eisai, she worked at Novartis for more than two decades in a variety of roles of increasing responsibility, including sales, market access, marketing, brand leadership and general management. She started her career with Novartis in the UK, then transferred to the U.S. to join Novartis Oncology, where she led launches in breast cancer, pancreatic cancer, rare diseases and cancer supportive care and gained leadership experience in a variety of disciplines across a number of regions. She holds a degree in geography and biological sciences from Lancaster University, England.
Scott Fields, M.D., joined from Vertex Pharmaceuticals, where he was vice president and head of Clinical Oncology and responsible for the global development of all oncology assets. Prior to joining Vertex, he held a number of leadership roles within the pharmaceutical industry at Smithkline Beecham, Amgen, Eisai and Arno and gained experience as a practicing oncologist in academic settings. He earned his medical degree from SUNY Downstate and did his Internal Medicine and Hematology/Oncology training at Columbia University Medical Center.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.us.
